Principal, Levine Media Group, host of The Bio Report and RARECast podcasts, award-winning journalist focused on the life sciences.
Berkeley, CA
- Tweets 3,242
- Following 585
- Followers 1,724
- Likes 180
Steven Ringel, founder and CEO of Nome, discusses helping families and patient groups evaluate genetic-medicine options, shape development plans, and connect with partners to advance individualized therapies toward the clinic. @globalgenes #RARECast
globalgenes.org/raredaily/en…
1
63
Catharina Svanborg @HamletBioPharma , discusses Alpha1H—an experimental synthetic peptide inspired by a protein complex in human breast milk—designed to target bladder tumor cells while sparing healthy tissue.
thebioreport.podbean.com/e/e…
64
Catharina Svanborg @HamletBioPharma , discusses Alpha1H—an experimental synthetic peptide inspired by a protein complex in human breast milk—designed to target bladder tumor cells while sparing healthy tissue.
thebioreport.podbean.com/e/e…
59
Per Lundin of Evox Therapeutics, discusses the promise and limitations of exosome-enabled gene editing, how Evox is prioritizing its pipeline, and what it will take to establish this emerging therapeutic strategy in the clinic. @GlobalGenes #RARECast
globalgenes.org/raredaily/us…
68
Eric Scheeff, CSO of Idefine, discusses progress in building the scientific foundation for a treatment for the neurodevelopmental condition Kleefstra syndrome, the role of its patient community, and its work ahead. @globalgenes #RARECast
globalgenes.org/raredaily/bu…
58
Julie Raskin, CEO of Congenital Hyperinsulinism International discusses how an NICU crisis gave rise to the organization and its global fight for better treatments. @globalgenes #RARECast
globalgenes.org/raredaily/th…
60
Sid Kerkar @AllerGeneAI on the company’s efforts to reset mast cells in people with severe allergies, the potential for mRNA and lipid nanoparticle delivery to simplify and broaden access to CAR-T therapy, and what it will take to advance the platform. thebioreport.podbean.com/e/r…
63
Here's what you may have missed in August from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.
linkedin.com/pulse/gileads-s…
52
Doug Love @annexonbio discusses Guillain-Barré syndrome, the limits of current nonspecific care, and Annexon’s targeted approach to stopping the complement-driven inflammatory cascade at its source.
globalgenes.org/raredaily/st…
62
Mayank Gandhi, co-founder and CEO of @NEOKBio , discusses the company’s bispecific ADC platform, its two clinical programs, and its strategy to develop more selective therapies for patients with advanced solid tumors.
thebioreport.podbean.com/e/i…
1
1
59
Alan Trounson Evinco discusses the company’s effort to develop NK cell-derived particles to cross the blood-brain barrier, curb neuroinflammation, and promote amyloid clearance in Alzheimer’s.
thebioreport.podbean.com/e/t…
53
Could sickle cell be cured before birth? @pshangaris @KingsCollegeLon discusses the PERICLES Project and prenatal gene editing’s promise. @GlobalGenes #RARECast globalgenes.org/raredaily/cu…
53
Unexplained weakness isn’t just aging. @Myasthenia Gravis Association’s Allison Foss and @ClevelandClinic John Morren discuss red flags for late-onset neuromuscular disease and a new clinical diagnostic tool. @globalgenes #RARECast
globalgenes.org/raredaily/sp…
74
Half of ischemic stroke patients face poor outcomes. Revalesio’s Greg Archambeau discusses how the company’s oxygenated saline therapy, RNS60, may help protect the brain after stroke, reduce tissue damage, and change the economics of stroke care.
thebioreport.podbean.com/e/p…
68
.@ChiesiGRD has evolved through dealmaking, expanding into CRISPR and BBB tech—Giacomo Chiesi shares vision @GlobalGenes globalgenes.org/raredaily/ex…
82
The autoimmune condition Type 1 diabetes is managed, not prevented. Zag Bio CEO Jason Cole discusses targeting immune tolerance via thymus-homing antibodies to induce Tregs. thebioreport.podbean.com/e/t…
43
Most drugs miss key GPCR targets. @ChristofferNorn SkapeBio discusses how the company is using AI-designed mini proteins to unlock them—combining strengths of biologics and small molecules to open new therapeutic frontiers.
thebioreport.podbean.com/e/u…
47
Warner Biddle, CEO of @Kyverna_Tx, discusses the company’s B cell–targeting cell therapy and their potential to reset autoimmune disease @globalgenes #RARECast
globalgenes.org/raredaily/a-…
46
.@AAlphaBio @DavidAYounger discusses why more wet lab data and infrastructure will be needed for AI drug discovery than most people expect, why current public datasets fall short, and the company’s business model.
thebioreport.podbean.com/e/a…
1
38
Multispecific antibodies unlock new biology—but safety risks are often designed in. @labgeni_us' @AngusSinclair discusses how its AI platform engineers multi-specific T‑cell engagers that are both potent and selective in solid tumors. thebioreport.podbean.com/e/t…
67